<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>A new class of sleep drugs draws Wall Street’s attention — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">A new class of sleep drugs draws Wall Street’s attention</h2>
    <div class="badge">2025-09-08T15:48:00+00:00</div>
    <ul>
      <li>Takeda additionally said the median weekly rates of cataplexy decreased more than 80% for oveporexton-treated patients during its studies.</li>
<li>The exam has several rounds, with each lasting roughly 40 minutes.</li>
<li>The median number of days per week that patients experienced no cataplexy had also grown, from 0 to between 4 and 5.</li>
<li>This story was originally published on BioPharma Dive.</li>
<li>Johnson &amp; Johnson, for instance, hopes that by blocking orexin-2, its experimental medicine seltorexant can be used to combat insomnia in patients with major depression.</li>
<li>That protein, called orexin-2, helps regulate important body functions like appetite, arousal and wakefulness, which has in turn made it a promising target for drug companies.</li>
<li>The furthest along in this pursuit is Takeda Pharmaceutical with its drug oveporexton, which recently met the main and secondary goals of two late-stage clinical trials that focused on the most common, “Type 1” form of n</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=A new class of sleep drugs draws Wall Street’s attention\n• Takeda additionally said the median weekly rates of cataplexy decreased more than 80% for oveporexton-treated patients during its studies.\n• The exam has several rounds, with each lasting roughly 40 minutes.\n• The median number of days per week that patients experienced no cataplexy had also grown, from 0 to between 4 and 5.\n• This story was originally published on BioPharma Dive.\n• Johnson &amp; Johnson, for instance, hopes that by blocking orexin-2, its experimental medicine seltorexant can be used to combat insomnia in patients with major depression.\n• That protein, called orexin-2, helps regulate important body functions like appetite, arousal and wakefulness, which has in turn made it a promising target for drug companies.\n• The furthest along in this pursuit is Takeda Pharmaceutical with its drug oveporexton, which recently met the main and secondary goals of two late-stage clinical trials that focused on the most common, “Type 1” form of n" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/ce2a065f-143b-3c6c-bc14-02b2564fdae8/a-new-class-of-sleep-drugs.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>